Javier Olascoaga

San Sebastian, PV, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

Journal: PloS one

Published: June 14, 2021

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.

Journal: Neurology

Published: May 04, 2021

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

Journal: Brain : a journal of neurology

Published: January 05, 2020

Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.

Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 01, 2019

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

Journal: Multiple sclerosis and related disorders

Published: October 03, 2019

Early clinical markers of aggressive multiple sclerosis.

Early clinical markers of aggressive multiple sclerosis.

Journal: Brain : a journal of neurology

Published: August 22, 2019

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 10, 2019

ABO blood group distributions in multiple sclerosis patients from Basque Country; O- as a protective factor.

ABO blood group distributions in multiple sclerosis patients from Basque Country; O- as a protective factor.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: July 11, 2019

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Journal: Neurology

Published: June 13, 2019

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Journal: Multiple sclerosis and related disorders

Published: September 11, 2018

The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients.

The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients.

Journal: International journal of molecular sciences

Published: July 20, 2018

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].

Journal: Multiple sclerosis and related disorders

Published: February 23, 2018

Showing 1-12 of 65

Last Updated: 09/26/2026